The details bedevil DCOR.
Calcium-free oral phosphorus binders were heralded as a striking new development for patients with chronic kidney disease, promising a reduction in morbidity and mortality from cardiovascular disease. Sevelamer hydrochloride was the first such drug introduced to the market. Dialysis Clinical Outcomes Revisited (DCOR) is an outcomes study on the effect of sevelamer compared with calcium-based phosphorus binders in dialysis patients. It does not show a clear superiority of one compound over the other.